Az egyetem munkatársai által beadott védőoltások száma - 2023. január 22.
545262 Összes oltás

1: Müller D, Győrffy B. DNA methylation-based diagnostic, prognostic, and
predictive biomarkers in colorectal cancer. Biochim Biophys Acta Rev Cancer.
2022 May;1877(3):188722. doi: 10.1016/j.bbcan.2022.188722. Epub 2022 Mar 17.
PMID: 35307512.

2: Bell HN, Huber AK, Singhal R, Korimerla N, Rebernick RJ, Kumar R, El-Derany
MO, Sajjakulnukit P, Das NK, Kerk SA, Solanki S, James JG, Kim D, Zhang L, Chen
B, Mehra R, Frankel TL, Győrffy B, Fearon ER, Pasca di Magliano M, Gonzalez FJ,
Banerjee R, Wahl DR, Lyssiotis CA, Green M, Shah YM. Microenvironmental
ammonia enhances T cell exhaustion in colorectal cancer. Cell Metab. 2023 Jan
3;35(1):134-149.e6. doi: 10.1016/j.cmet.2022.11.013. Epub 2022 Dec 16. PMID:
36528023.

3: Viganò L, Locatelli A, Ulisse A, Galbardi B, Dugo M, Tosi D, Tacchetti C,
Daniele T, Győrffy B, Sica L, Macchini M, Zambetti M, Zambelli S, Bianchini G,
Gianni L. Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6
Inhibition Triggers Sustained Senescence in Estrogen Receptor- and
ErbB2-positive Breast Cancer. Clin Cancer Res. 2022 May 13;28(10):2167-2179.
doi: 10.1158/1078-0432.CCR-21-3185. PMID: 35254385; PMCID: PMC9595107.

4: Kovács SA, Győrffy B. Transcriptomic datasets of cancer patients treated with
immune-checkpoint inhibitors: a systematic review. J Transl Med. 2022 May
31;20(1):249. doi: 10.1186/s12967-022-03409-4. PMID: 35641998; PMCID:
PMC9153191.

5: Menyhárt O, Győrffy B, Szabó A. Gyermekkori genetikai rendellenességek
diagnosztikája újgenerációs szekvenálással [Diagnosis of genetic disorders in
childhood with next-generation sequencing]. Orv Hetil. 2022 Dec
18;163(51):2027-2040. Hungarian. doi: 10.1556/650.2022.32688. PMID: 36528826.

6: Munkácsy G, Santarpia L, Győrffy B. Gene Expression Profiling in Early Breast
Cancer-Patient Stratification Based on Molecular and Tumor Microenvironment
Features. Biomedicines. 2022 Jan 24;10(2):248. doi:
10.3390/biomedicines10020248. PMID: 35203458; PMCID: PMC8869155.

7: Menyhart O, Weltz B, Győrffy B.  MultipleTesting.com: A tool for
life science researchers for multiple hypothesis testing correction. PLoS One.
2022 Sep 9;17(9):e0274662. doi: 10.1371/journal.pone.0274662. Erratum for: PLoS
One. 2021 Jun 9;16(6):e0245824. PMID: 36084071; PMCID: PMC9462819.

8: Miskey C, Botezatu L, Temiz NA, Gogol-Döring A, Bartha Á, Győrffy B,
Largaespada DA, Ivics Z, Sebe A. In Vitro Insertional Mutagenesis Screen
Identifies Novel Genes Driving Breast Cancer Metastasis. Mol Cancer Res. 2022
Oct 4;20(10):1502-1515. doi: 10.1158/1541-7786.MCR-21-0772. PMID: 35687718.

9: Ágoston EI, Acs B, Herold Z, Fekete K, Kulka J, Nagy A, Mühl D, Mohacsi R,
Dank M, Garay T, Harsanyi L, Győrffy B, Szasz AM. Deconstructing Immune Cell
Infiltration in Human Colorectal Cancer: A Systematic Spatiotemporal Evaluation.
Genes (Basel). 2022 Mar 25;13(4):589. doi: 10.3390/genes13040589. PMID:
35456394; PMCID: PMC9024576.

10: López-Cade I, García-Barberán V, Cabañas Morafraile E, Díaz-Tejeiro C, Saiz-
Ladera C, Sanvicente A, Pérez Segura P, Pandiella A, Győrffy B, Ocaña A. Genomic
mapping of copy number variations influencing immune response in breast cancer.
Front Oncol. 2022 Sep 1;12:975437. doi: 10.3389/fonc.2022.975437. PMID:
36119512; PMCID: PMC9476651.

11: Pálinkás HL, Pongor L, Balajti M, Nagy Á, Nagy K, Békési A, Bianchini G,
Vértessy BG, Győrffy B. Primary Founder Mutations in the <i>PRKDC</i> Gene
Increase Tumor Mutation Load in Colorectal Cancer. Int J Mol Sci. 2022 Jan
6;23(2):633. doi: 10.3390/ijms23020633. PMID: 35054819; PMCID: PMC8775830.

12: Dmello C, Sonabend A, Arrieta VA, Zhang DY, Kanojia D, Chen L, Gould A,
Zhang J, Kang SJ, Winter J, Horbinski C, Amidei C, Győrffy B, Cordero A, Chang
CL, Castro B, Hsu P, Ahmed AU, Lesniak MS, Stupp R, Sonabend AM. Translocon-
associated Protein Subunit SSR3 Determines and Predicts Susceptibility to
Paclitaxel in Breast Cancer and Glioblastoma. Clin Cancer Res. 2022 Jul
15;28(14):3156-3169. doi: 10.1158/1078-0432.CCR-21-2563. PMID: 35552677.

13: Olah C, Reis H, Hoffmann MJ, Mairinger F, Ting S, Hadaschik B, Krafft U,
Grünwald V, Nyirady P, Varadi M, Győrffy B, Kiss A, Szekely E, Sjödahl G,
Szarvas T. Predictive value of molecular subtypes and APOBEC3G for adjuvant
chemotherapy in urothelial bladder cancer. Cancer Med. 2022 Oct 7. doi:
10.1002/cam4.5324. Epub ahead of print. PMID: 36204983.

14: Alcaraz-Sanabria A, Cabañas Morafraile E, Fernández-Hinojal G, Velasco G,
Pérez-Segura P, Pandiella A, Győrffy B, Ocaña A. Transcriptomic Mapping of Non-
Small Cell Lung Cancer <i>K-RAS</i> p.G12C Mutated Tumors: Identification of
Surfaceome Targets and Immunologic Correlates. Front Immunol. 2022 Feb
1;12:786069. doi: 10.3389/fimmu.2021.786069. PMID: 35178045; PMCID: PMC8843839.

15: Pai P, Wang G, Teo WW, Raez-Rodriguez D, Gabrielson KL, Győrffy B, Downs BM,
Aggarwal A, Sukumar S. HOXA5-Mediated Stabilization of IκBα Inhibits the NF-κB
Pathway and Suppresses Malignant Transformation of Breast Epithelial Cells.
Cancer Res. 2022 Oct 17;82(20):3802-3814. doi: 10.1158/0008-5472.CAN-21-4277.
PMID: 36166646; PMCID: PMC9588663.

16: Palassin P, Lapierre M, Bonnet S, Pillaire MJ, Győrffy B, Teyssier C,
Jalaguier S, Hoffmann JS, Cavaillès V, Castet-Nicolas A. RIP140 regulates
<i>POLK</i> gene expression and the response to alkylating drugs in colon cancer
cells. Cancer Drug Resist. 2022 May 7;5(2):401-414. doi: 10.20517/cdr.2021.133.
PMID: 35800380; PMCID: PMC9255241.

17: Harrod A, Lai CF, Goldsbrough I, Simmons GM, Oppermans N, Santos DB,
Győrffy B, Allsopp RC, Toghill BJ, Balachandran K, Lawson M, Morrow CJ,
Surakala M, Carnevalli LS, Zhang P, Guttery DS, Shaw JA, Coombes RC,
Buluwela L, Ali S. Genome engineering for estrogen receptor mutations
reveals differential responses to anti-estrogens and new prognostic gene
signatures for breast cancer. Oncogene. 2022 Oct;41(44):4905-4915.
doi: 10.1038/s41388-022-02483-8. Epub 2022 Oct 5. PMID: 36198774;
PMCID: PMC7613769.

18: Munkácsy G, Herman P, Győrffy B. Comparison of scientometric achievements
at PhD and scientific output ten years later for 4,790 academic researchers.
PLoS One. 2022 Jul 27;17(7):e0271218. doi: 10.1371/journal.pone.0271218. PMID:
35895676; PMCID: PMC9328526.

19: Hegedüs L, Livingstone E, Bánkfalvi Á, Viehof J, Enyedi Á, Bilecz Á, Győrffy
B, Baranyi M, Tőkés AM, Gil J, Marko-Varga G, Griewank KG, Zimmer L, Váraljai R,
Sucker A, Zaremba A, Schadendorf D, Aigner C, Hegedüs B. The Prognostic
Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications
for Immune Checkpoint Inhibition. Int J Mol Sci. 2022 Mar 19;23(6):3324. doi:
10.3390/ijms23063324. PMID: 35328746; PMCID: PMC8949876.

20: Jacquier V, Gitenay D, Fritsch S, Bonnet S, Győrffy B, Jalaguier S, Linares
LK, Cavaillès V, Teyssier C. RIP140 inhibits glycolysis-dependent proliferation
of breast cancer cells by regulating GLUT3 expression through transcriptional
crosstalk between hypoxia induced factor and p53. Cell Mol Life Sci. 2022 May
3;79(5):270. doi: 10.1007/s00018-022-04277-3. PMID: 35501580; PMCID: PMC9061696.

21: Kothalawala WJ, Győrffy B. Transcriptomic and cellular content analysis of
colorectal cancer by combining multiple independent cohorts. Clin Transl
Gastroenterol. 2022 Jul 20. doi: 10.14309/ctg.0000000000000517. Epub ahead of
print. PMID: 35858620.

22: Regan JL, Schumacher D, Staudte S, Steffen A, Lesche R, Toedling J, Jourdan
T, Haybaeck J, Golob-Schwarzl N, Mumberg D, Henderson D, Győrffy B, Regenbrecht
CRA, Keilholz U, Schäfer R, Lange M. Identification of a neural development gene
expression signature in colon cancer stem cells reveals a role for <i>EGR2</i>
in tumorigenesis. iScience. 2022 May 31;25(7):104498. doi:
10.1016/j.isci.2022.104498. PMID: 35720265; PMCID: PMC9204726.

23: Ladányi A, Rásó E, Barbai T, Vízkeleti L, Puskás LG, Kovács SA, Győrffy B,
Tímár J. Identification of a Tumor Cell Associated Type I IFN Resistance Gene
Expression Signature of Human Melanoma, the Components of Which Have a
Predictive Potential for Immunotherapy. Int J Mol Sci. 2022 Feb 28;23(5):2704.
doi: 10.3390/ijms23052704. PMID: 35269844; PMCID: PMC8911010.

24: Tibor Fekete J, Győrffy B. A unified platform enabling biomarker ranking and
validation for 1562 drugs using transcriptomic data of 1250 cancer cell lines.
Comput Struct Biotechnol J. 2022 Jun 6;20:2885-2894. doi:
10.1016/j.csbj.2022.06.007. PMID: 35765648; PMCID: PMC9198269.

25: Ding X, Sharko AC, McDermott MSJ, Schools GP, Chumanevich A, Ji H, Li J,
Zhang L, Mack ZT, Sikirzhytski V, Shtutman M, Ivers L, O’Donovan N, Crown J,
Győrffy B, Chen M, Roninson IB, Broude EV. Inhibition of CDK8/19 Mediator kinase
potentiates HER2-targeting drugs and bypasses resistance to these agents
in vitro and in vivo. Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2201073119.
doi: 10.1073/pnas.2201073119. Epub 2022 Aug 1. PMID: 35914167; PMCID:
PMC9371674.

26: Olah C, Hahnen C, Nagy N, Musial J, Varadi M, Nyiro G, Gyorffy B, Hadaschik
B, Rawitzer J, Ting S, Sjödahl G, Hoffmann MJ, Reis H, Szarvas T. A quantitative
polymerase chain reaction based method for molecular subtype classification of
urinary bladder cancer-Stromal gene expressions show higher prognostic values
than intrinsic tumor genes. Int J Cancer. 2022 Mar 1;150(5):856-867. doi:
10.1002/ijc.33809. Epub 2021 Oct 2. PMID: 34536301.

27: Riecks J, Parnigoni A, Győrffy B, Kiesel L, Passi A, Vigetti D, Götte M. The
hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with
prognosis, cell viability and spheroid formation capacity in ovarian cancer. J
Cancer Res Clin Oncol. 2022 Dec;148(12):3399-3419. doi:
10.1007/s00432-022-04127-6. Epub 2022 Jun 29. PMID: 35767191; PMCID: PMC9587083.

28: Mazzeschi M, Sgarzi M, Romaniello D, Gelfo V, Cavallo C, Ambrosi F, Morselli
A, Miano C, Laprovitera N, Girone C, Ferracin M, Santi S, Rihawi K, Ardizzoni A,
Fiorentino M, D’Uva G, Győrffy B, Palmer R, Lauriola M. The autocrine loop of
ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular
subtype 1 colon cancer. J Exp Clin Cancer Res. 2022 Mar 29;41(1):113. doi:
10.1186/s13046-022-02309-1. PMID: 35351152; PMCID: PMC8962179.

29: Kahl I, Mense J, Finke C, Boller AL, Lorber C, Győrffy B, Greve B, Götte M,
Espinoza-Sánchez NA. The cell cycle-related genes RHAMM, AURKA, TPX2, PLK1,
and PLK4 are associated with the poor prognosis of breast cancer patients.
J Cell Biochem. 2022 Mar;123(3):581-600. doi: 10.1002/jcb.30205.
Epub 2022 Jan 10. PMID: 35014077.

30: Jobbágy A, Kiss N, Meznerics FA, Farkas K, Plázár D, Bozsányi S, Fésűs L,
Bartha Á, Szabó E, Lőrincz K, Sárdy M, Wikonkál NM, Szoldán P, Bánvölgyi A.
Emergency Use and Efficacy of an Asynchronous Teledermatology System as a Novel
Tool for Early Diagnosis of Skin Cancer during the First Wave of COVID-19
Pandemic. Int J Environ Res Public Health. 2022 Feb 25;19(5):2699. doi:
10.3390/ijerph19052699. PMID: 35270391; PMCID: PMC8910370.

31: Mahdi M, Hermán L, Réthelyi JM, Bálint BL. Potential Role of the
Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19. Int J
Mol Sci. 2022 Mar 30;23(7):3812. doi: 10.3390/ijms23073812. PMID: 35409171;
PMCID: PMC8998734.

32: Laczik M, Erdős E, Ozgyin L, Hevessy Z, Csősz É, Kalló G, Nagy T, Barta E,
Póliska S, Szatmári I, Bálint BL. Extensive proteome and functional genomic
profiling of variability between genetically identical human B-lymphoblastoid
cells. Sci Data. 2022 Dec 10;9(1):763. doi: 10.1038/s41597-022-01871-9. PMID:
36496436; PMCID: PMC9741606.

33: Szeitz B, Megyesfalvi Z, Woldmar N, Valkó Z, Schwendenwein A, Bárány N, Paku
S, László V, Kiss H, Bugyik E, Lang C, Szász AM, Pizzatti L, Bogos K, Hoda MA,
Hoetzenecker K, Marko-Varga G, Horvatovich P, Döme B, Schelch K, Rezeli M. In-
depth proteomic analysis reveals unique subtype-specific signatures in human
small-cell lung cancer. Clin Transl Med. 2022 Sep;12(9):e1060. doi:
10.1002/ctm2.1060. PMID: 36149789; PMCID: PMC9506422.